linjc16/ctgov huggingface dataset:
Effects of Alcohol History on Effects of Sevoflurane and Nitrous Oxide - 13

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the effects of alcohol history on the subjective and reinforcing effects of sevoflurane and nitrous oxide in healthy volunteers. All subjects underwent psychomotor testing during 4 sessions of placebo, drug/placebo, and choice of intervention.

Official Title
-----------------
Effects of Alcohol History on Effects of Sevoflurane and Nitrous Oxide

Conditions
-----------------
Alcohol-Related Disorders, Opioid-Related Disorders, Substance-Related Disorders

Intervention / Treatment
-----------------
* Drug: 30% Nitrous oxide
* Other: Placebo
* Drug: 0.2% sevoflurane
* Drug: 0.4% sevoflurane
* Drug: 0.6% sevoflurane


Participation Criteria
=================
Eligibility Criteria
-----------------
Please contact site for information.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Moderate drinking adults<br> | Drug: 30% Nitrous oxide<br> <br> Other: Placebo<br>* No drug (100% oxygen)<br>Drug: 0.2% sevoflurane<br> <br> Drug: 0.4% sevoflurane<br> <br> Drug: 0.6% sevoflurane<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mood |  | Baseline, inhalation, recovery | 
| Psychomotor performance |  | Baseline, inhalation, recovery | 
| Choice of drug vs placebo |  | After placebo and drug in each session | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
nitrous oxide, sevoflurane, ethanol, subjective effects, healthy volunteer
Development of a New Method for Analgesia

Study Overview
=================
Brief Summary
-----------------
Aim: To examine a new method to perform local anesthesia in order to diminish the inconvenience by the procedure in patients before performing intubation or oesophagogastroduodenoscopy.

Detailed Description
-----------------
A phase one and two study. part one is performed as a single arm unblinded uncontrolled study in 16 obese patients undergoing awake intubation (investigational pill). The second part is a phase two study randomized single blinded study in 100 patient attending a day case endoscopy unit for oesophagogastroduodenoscopy (investigational pill versus lidocaine suspension).

Official Title
-----------------
Phase One Study and Two of a New Method for Local Analgesia

Conditions
-----------------
Analgesia

Intervention / Treatment
-----------------
* Drug: CRC-Pharma 001
* Drug: lidocaine suspension


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients admitted for adipositas surgery Patients who attend for oesophagogastroduodenoscopy. Exclusion Criteria: Severe psychiatric diseases Alcohol abuse

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: single arm<br> | Drug: CRC-Pharma 001<br>* 50 mg<br>Drug: lidocaine suspension<br>* 5.0 ml lidocaine suspension(20mg/ml) adm. 10 min. before oesophagogastroduodenoscopy.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| VAS score |  | at day O and 3 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Questionnaire( examiner and patient) |  | performed at day 0 and 3 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Analgesia Tests, Analog Pain Scale, Pain Measurement
Recording High Frequency Oscillations in Patients With Tumors and Epilepsy

Study Overview
=================
Brief Summary
-----------------
The investigators want to characterize high-frequency oscillations (HFOs) in intracranial recordings, which may occur as markers of epileptogenic tissue and also under physiological stimulation. The investigators want to show that recording of high-frequency oscillations (HFOs) is feasible in our project population both intraoperatively and during presurgical physiological conditions.

Official Title
-----------------
Recording High Frequency Oscillations in Patients With Tumors and Epilepsy.

Conditions
-----------------
Tumor, Epilepsy

Intervention / Treatment
-----------------
* Behavioral: cognitive testing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients intend to be treated at the Klinik für Neurochirurgie Patients fall into one of the patient groups: (1) Patients with symptomatic epilepsy with focal and/or secondary generalized seizures resistant to medication where a neurosurgical resection is considered as an intervention of epilepsy surgery. (2)Patients where a tumor is planned to be resected that has caused preoperative seizures. (3) Patients where a tumor is planned to be resected that has not caused preoperative seizures. Male and Female subjects 18 years to 99 years of age Written informed consent after participants' information Exclusion Criteria: contraindications on ethical grounds known or suspected non-compliance, drug or alcohol abuse, enrolment into a clinical trial within last 4 weeks

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| epilepsy<br>epilepsy patients | Behavioral: cognitive testing<br>* patients perform simple tasks like watching a video or memorizing items<br>|
| tumor with epilepsy<br>tumor patients with epileptic seizures | Behavioral: cognitive testing<br>* patients perform simple tasks like watching a video or memorizing items<br>|
| tumor without epilepsy<br>tumor patients without epileptic seizures | Behavioral: cognitive testing<br>* patients perform simple tasks like watching a video or memorizing items<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HFO (high-frequency oscillations) occurrence |  | 1 week |
Comparison of Two Neuromuscular Monitors

Study Overview
=================
Brief Summary
-----------------
Different neuromuscular monitors may be available in the same care structure. Two different monitors are available in the investigators' institution in the operative room and the recovery room. However, these two monitors have not been compared and may not be interchangeable. Starting the monitoring with one device and continuing with another device may be inaccurate and may lead to inadequate medical decisions. The investigators therefore conducted this observational study to compare the two devices available in our institution.

Official Title
-----------------
Comparison of Two Neuromuscular Monitors

Conditions
-----------------
Neuromuscular Monitoring

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing vascular surgery under general anesthesia and requiring neuromuscular blockade for intubation or surgery Exclusion Criteria: Pregnancy or feeding Any pathology or medication that may impair neuromuscular conduction or muscular response of the ulnar nerve stimulation American Society of Anesthesiology [4] physical status Allergy or contraindication of neuromuscular blocking agents

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to recover T4/T1 > 90% | After muscle relaxant injection, we measure the time needed for the muscular response to disappear and to completely recover during the operation (which takes in average 2 hours). | Time between muscle relaxant injection and: intubation; recovery of 4 responses on the train of four (TOF); recovery of T4/T1 >40%; recovery of T4/T1>90% average 2 hours |
Sleep Disorders Pre and Post Liver Transplantation

Study Overview
=================
Brief Summary
-----------------
Sleep disturbance and sexual dysfunction are common complaints of patients with cirrhosis . The term sleep disturbance describes insomnia, poor quality sleep, circadian rhythm disorders and obstructive sleep apnea and is associated with reduced health-related quality of life (HRQoL) score indices. Sleep and sexual disorders have only been formally evaluated in small studies in these patients and to date, no studies have objectively assessed these patients. In addition, no studies have been performed in these patients after liver transplantation. The investigators' hypothesis is that sleep and sexual disturbance is commonly seen in patients with advanced cirrhosis and improves after liver transplantation. However, despite this, HRQoL remain impaired because of residual sleep disturbance.This study will be unique in providing cross-sectional follow-up of patients with cirrhosis at baseline and after liver transplantation (> 6 months).

Official Title
-----------------
Prospective Study to Evaluate Sleep Disturbance in Patients With Liver Disease Pre and Post Liver Transplantation

Conditions
-----------------
Liver Cirrhosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Liver cirrhosis Comprehend and read English On liver transplantation list or post-liver transplantation Exclusion Criteria: Non-English speaking < 18 years and > 85 yrs

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sleep disturbances in patients with advanced cirrhosis |  | 18 months |
Trainee Involvement in ERCP Risk Score

Study Overview
=================
Brief Summary
-----------------
The study aims to evaluate factors associated with an increased risk of procedure related adverse events (including tecnical failure) of endoscopic retrograde cholangiopancreatography procedures (ERCP) conducted in a teaching setting, with trainee involvement.

Detailed Description
-----------------
The study aims to evaluate factors associated with an increased risk of procedure related adverse events (including tecnical failure) of endoscopic retrograde cholangiopancreatography procedures (ERCP) conducted in a teaching setting, with trainee involvement. It has previously shown that ERCP procedures with trainee involvement have no additional risk for the patient, but we aim to evaluate whether a subgroup of high-risk procedures can be identified to allow an improvement of the teaching of ERCP, including identifying some high risk features that might indicate that trainee involvement should not be warranted. Briefly, the study is observational in nature and aims to gather clinical data about the patient and technical data about the procedure (including the degree of trainee involvement( to assess which (if any) procedures carry a higher risk for the patient in a training setting. data will be gathered using a standard report form completed by the attending endoscopist at the end of each procedure; the form will then be updated at 30days interval with data about potential adverse events. Patient identity will be protected throughout the study as per regulations in each institution and country; also all patients will sign an informed consent prior to the endoscopic procedure and study enrollment.

Official Title
-----------------
Trainee Involvement in ERCP Risk Score

Conditions
-----------------
Bile Duct Diseases, Pancreas Cancer

Intervention / Treatment
-----------------
* Procedure: ERCP


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients undergoing ERCP in the participating centers informed consent signed prior to the procedure Exclusion Criteria: refusal to participate / sign the informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Trainee Group<br>Patients who undergo ERCPs with trainee involvement | Procedure: ERCP<br>* endoscopic retrograde cholangiopancreatography<br>|
| control group<br>Patients who undergo ERCPs without any trainee involvement | Procedure: ERCP<br>* endoscopic retrograde cholangiopancreatography<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| any procedure related adverse outcome | including but not limited to cholangitis, perforation, bleeding, technical failure, pancreatitis | 30 days |
Prognosis Value of Non-invasive Methods for the Diagnosis of Chronic Liver Disease

Study Overview
=================
Brief Summary
-----------------
The aim of this retrospective and prospective study is to evaluate the 20-year prognosis value of non-invasive methods for the diagnosis of chronic liver disease for predicting survival and complications of cirrhosis.

Detailed Description
-----------------
All consecutive patients with chronic liver disease will be followed during 20 years.

Official Title
-----------------
Prognosis Value of Non-invasive Methods for the Diagnosis of Chronic Liver Disease. a Retrospective and Prospective 20-year Follow-up.

Conditions
-----------------
Chronic Liver Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: chronic hepatitis C chronic hepatitis B alcohol liver disease non alcoholic liver disease Exclusion Criteria: ascitis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Chronic liver disease<br>all patients with chronic liver disease followed using non-invasive methods | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival |  | 20 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Survival without liver complications |  | 20 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
diagnosis, survival, non-invasive method, cirrhosis, FibroScan
Clinical Diagnosis of Teenagers Admitted to Pediatric Departments

Study Overview
=================
Brief Summary
-----------------
This study intends to analyze the clinical characteristics of teenagers admitted to pediatric wards due to organic illness and non organic diagnosis, including patients suffering from chronic diseases and comorbidity.

Detailed Description
-----------------
The intention is to summarize the data from year 2000 to 2007 af all the teenagers aged 14 ys to 20 yes admitted to the pediatric wards at the Ha'Emek Medical Center. The demographic and clinical date will be summarized.

Official Title
-----------------
The Purpose of This Study is to Analyze the Clinical Characteristics of Teenagers Admitted to Pediatric Departments

Conditions
-----------------
Anorexia, Thalassemia, Sickle Cell Anemia, Chronic Renal Failure, Suicide Attempt

Intervention / Treatment
-----------------
* Other: Observational


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All the patients ages 14 to 20 ys admitted to the pediatric ward. Exclusion Criteria: No exclusion criteria relevant.

Ages Eligible for Study
-----------------
Minimum Age: 14 Years
Maximum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| A<br>Acute organic diseases | Other: Observational<br>* Data summary only<br>|
| B<br>Patients with chronic diseases | Other: Observational<br>* Data summary only<br>|
| C<br>Patients with psychiatric diagnosis | Other: Observational<br>* Data summary only<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Analyzing the characteristics of Teenagers Admitted to Pediatric Departments | Analyzing the characteristics of Teenagers Admitted to Pediatric Departments | One year |
Diagnostic and Prognostic Significance of Computerized Cytologic Morphometry of the Thyroid Neoplasm

Study Overview
=================
Brief Summary
-----------------
The prevalence of thyroid nodule is worldwide high. About 40% of normal population has thyroid nodules and about 5% are malignancy. It is important to differentiate malignancy from benign nodules because the management is completely different. Nowadays, the gold standard is fine needle aspiration cytology (FNAC) examination. The overall sensitivity and specificity is fair ( 90%), but still has its limitation that some results are indeterminate in about 15% of the nodules. These obstacles are especially troublesome for papillary and follicular thyroid cancer that leads to delayed diagnosis, incomplete resection, and repeated operation. Preoperative evaluation of the prognosis is extraordinary important for cancer management. However, current prognostic scoring systems is only applicable after surgery. Hence, we urgently need a better risk-stratification system for individual-tailored treatment, and genetic-based computerized morphometry study seems to be the most realistic and promising one. The goal of this study is to propose a reliable method for diagnosis and prognosis of papillary thyroid cancer and follicular thyroid cancer through analyzing cellular morphologic characteristics.

Official Title
-----------------
Diagnostic and Prognostic Significance of Computerized Cytologic Morphometry of the Thyroid Neoplasm

Conditions
-----------------
Computerized Cytomorphometry

Intervention / Treatment
-----------------
* Other: computerized cytomorphometry


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients who previously had received thyroid fine needle aspiration cytology examination Exclusion Criteria: patients who are younger than 20 years old

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| thyroid cancer<br> | Other: computerized cytomorphometry<br>* use computer program to analyse the characteristics of thyroid cells obtained by fine needle aspiration cytology examination<br>|
| benign thyroid nodules<br> | Other: computerized cytomorphometry<br>* use computer program to analyse the characteristics of thyroid cells obtained by fine needle aspiration cytology examination<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cytomorphometry of the cells | cytologic characteristics of the cells | 2016/4/20-2026/4/20 |
An Open,Single-centre Pilot Study of Efficacy and Safety of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO)

Study Overview
=================
Brief Summary
-----------------
Assess efficacy and safety of topical MOB015B, applied daily during 48 weeks, in adults with fungal nail infection.

Conditions
-----------------
Distal Subungual Onychomycosis

Intervention / Treatment
-----------------
* Drug: MOB015B


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female 18 - 70 years DSO of at least one of the great toe(s) affecting 25 % to 75 % of the target nail. Positive culture for dermatophytes (i.e. Trichophyton species; T. rubrum or T. mentagrophytes) Signed written informed consent Exclusion Criteria: Proximal subungual onychomycosis. DSO of both great toenails where involvement has extended into the proximal portion of the target nail (unaffected proximal nail is less than 2 mm) Spike of onychomycosis extending to eponychium of the target nail Presence of dermatophytoma (defined as demarcated and localised thick masses of fungal hyphae and necrotic keratin between the nail plate and nail bed) on the target nail Other conditions than DSO known to cause abnormal nail appearance Topical antifungal treatment of the nails within 1 month before screening Systemic use of antifungal treatment within 3 months before screening History or signs of peripheral circulatory insufficiency and/or diabetic neuropathy Immunosuppression Participation in another clinical trial with an investigational drug or device during the previous 4 weeks before screening Known allergy to any of the tested treatment products A pregnancy test indicating pregnancy in a woman of childbearing potential at screening (visit 1) Pre-menopausal (last menstruation ≤ 1 year prior to screening) sexually active women who : are pregnant or nursing are not surgically sterile are of child bearing potential and not practising an acceptable method of birth control, or does not plan to continue practising an acceptable method of birth control throughout the trial (acceptable methods include intrauterine devices (IUD), oral, implantable or injectable contraceptives, diaphragm or cervical cap with intravaginal spermicide, condom with intravaginal spermicide or vasectomised partner)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: MOB015B|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The proportion of patients with mycological cure of the target nail,defined as negative fungal culture and negative direct microscopy at 60 weeks. |  | At 60 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
DSO